ALSTOM 15.875 € (+0,47 %) 
ALFEN 12.630 € (-7,40 %) 
X-FAB 5.890 € (-5,99 %) 
DSM FIRMENICH AG 88.500 € (+1,17 %) NSI N.V. 16.640 € (-1,30 %) INFOTEL 40.500 € (+0,50 %) SCHNEIDER ELECTRIC 294.000 € (-0,37 %) ASML HOLDING 1 507.600 € (-2,22 %) VIRIDIEN 90.100 € (-4,86 %) AHOLD DEL 31.550 € (-0,91 %) TME PHARMA 0.101 € (+27,85 %) CTP 14.360 € (+0,56 %) ING GROEP N.V. 29.870 € (-2,43 %) FDJ UNITED 22.120 € (+0,73 %) NANOBIOTIX 38.120 € (+8,17 %) AIRBUS 208.050 € (-0,83 %) PROSUS 37.895 € (+2,53 %) BE SEMICONDUCTOR 212.200 € (-4,54 %) WERELDHAVE 18.440 € (+0,22 %) KLARSEN 1.400 € (+25,00 %) BUREAU VERITAS 27.440 € (+0,07 %) HEINEKEN 71.980 € (-0,36 %) CBI 0.114 € (+13,27 %) MAGNUM 16.642 € (+1,48 %) GROUPE TERA 3.300 € (-11,76 %) TKH GROUP 48.460 € (-2,14 %) ICADE 18.700 € (-0,16 %) 
SHELL PLC 39.940 € (+0,39 %) ASM INTERNATIONAL 822.200 € (-2,40 %) SANOFI 78.560 € (+1,15 %) KAUFMAN ET BROAD 25.000 € (+0,81 %) FNAC DARTY 34.600 € (0,00 %) GROUPE GUILLIN 20.800 € (-0,95 %) WATERA 1.730 € (+12,34 %) KLEPIERRE 38.460 € (-0,31 %) CARREFOUR 15.770 € (-0,79 %) LNA SANTE 32.900 € (+0,92 %) VALNEVA 2.900 € (-1,59 %) STMICROELECTRONICS 43.890 € (-3,13 %) SOITEC 109.150 € (-4,00 %) BOIRON 26.200 € (0,00 %) AXA 43.980 € (-1,28 %) AKZO NOBEL 60.620 € (+0,70 %) VICAT 63.500 € (-0,47 %) 
ARCELORMITTAL SA 62.240 € (+0,81 %) BASSAC 43.300 € (-0,46 %) 
HAL TRUST 161.800 € (0,00 %) WORLDLINE 12.184 € (+1,16 %) BIOPHYTIS 0.132 € (+0,15 %) THALES 259.800 € (-2,33 %) MAUREL ET PROM 8.515 € (+1,92 %) BOUYGUES 46.700 € (+0,11 %) ABN AMRO BANK N.V. 40.090 € (-1,93 %) SMCP 6.585 € (+2,01 %) VEOLIA ENVIRON. 34.070 € (+0,68 %) SOCIETE GENERALE 77.020 € (-3,79 %) TOTALENERGIES 77.660 € (+0,99 %) KERING 260.050 € (+1,70 %) POUJOULAT 5.920 € (-6,62 %) BNP PARIBAS ACT.A 106.780 € (-2,39 %) |
19/08/2026 20:35
Revive Therapeutics Announces Proposed Shares for Debt SettlementTORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement"). The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE. The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com. For more information, please contact: Michael Frank SOURCE: Revive Therapeutics Ltd. View the original press release on ACCESS Newswire Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière